Celgene Oncology Exec Pehl Named Immunomedics President and CEO

Michael Pehl has been appointed president and CEO of cancer drug developer Immunomedics (NASDAQ: [[ticker:IMMU]]). Pehl comes to the Morris Plains, NJ, company from Celgene (NASDAQ: [[ticker:CELG]]), where he was president, hematology & oncology. He will start his new position at Immunomedics on Dec. 7.

Immunomedics is moving forward with sacituzumab govitecan, a breast cancer drug in Phase 3 studies whose rights Seattle Genetics (NASDAQ: [[ticker:SGEN]]) agreed to acquire in February. But that deal unwound following challenges from Immunomedics shareholders, who took control of the company’s board of directors.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan